Unless you’ve been working in isolation in Antarctica, you have undoubtedly heard about cannabidiol. More commonly known as CBD, the chemical has captivated the world with its range of medical applications. Extracted from hemp, CBD is one of over 100 cannabinoids that the cannabis plant produces.
CBDA or cannabidiolic acid is another cannabinoid produced by cannabis, and just like CBD, it doesn’t have psychoactive properties. However, the two chemicals differ in a number of ways;
CBDA is a precursor to cannabidiol. Before being converted to CBD, it is present in cannabis as CBDA. Heat has to be applied to CBDA to cause decarboxylation, a chemical process that removes the carboxyl group, converting the ‘inactive’ CBDA into cannabidiol. Heating the CBDA to around 270 degrees Fahrenheit as well as smoking are the most common ways of unlocking CBD.
Unlike cannabidiol, CBDA is rare. Due to its potent medical properties, CBD is in such extreme demand that the market has become saturated with hemp grown for CBD. Cannabidiolic acid, on the other hand, is quite rare. Most of the cannabis and hemp grown in the US is cured to unlock its THC and CBD potential respectively. This leaves very little raw, uncured cannabis with CBDA.
They interact differently with the body. The endocannabinoid system (ECS) is in charge of regulating immune response, sleep and other functions that contribute to homeostasis, the internal balance of the body.
CBD interacts with adenosine, vallinoid and serotonin receptors to help alleviate depression, anxiety, inflammation, and other conditions. It also inhibits the CPR55 receptors resulting in improved bone density and blood pressure.
CBDA, on the other hand, blocks COX-1 and COX-2 receptors which cause inflammation.
CBDA is more effective at alleviating nausea. An animal study conducted in 2013 compared the anti-nausea effects of cannabidiolic acid and cannabidiol. CBDA was much more potent, and it was able to inhibit vomiting as well as treat anticipatory nausea more effectively than CBD.
The study also found that CBDA demonstrated 100 greater food affinity with the 5HT1A receptor.
CBD has more medical applications than CBDA. Although decarboxylation unlocks CBD from CBDA, it leads to a loss of terpenes, so CBD doesn’t offer any terpene-related benefits. Still, this doesn’t take away from its abilities. Cannabidiol has been found to be effective against a plethora of ailments, ranging from anxiety, nausea and vomiting, and Multiple sclerosis to cancer, insomnia depression, and high blood pressure.
CBDA works effectively against arthritis, anxiety, nausea, vomiting and a few other conditions. However, since CBDA research is still in its early stages, its true potential may very well be hidden. Only time will tell.
Now that the CBD market is reaching maturity or saturation, experts think that CBD sector players like SinglePoint Inc. (OTCQB: SING) could already be turning to other cannabinoids, such as CBDA, as they plan for the future.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
